

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康宁杰瑞

ALPHAMAB ONCOLOGY

ALPHAMAB ONCOLOGY

康寧傑瑞生物製藥

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9966)

ADOPTION OF POST-IPO SHARE OPTION SCHEME

The board of directors (the “**Board**”) of Alphamab Oncology (the “**Company**”) announces that the Company plans to adopt a share option scheme (the “**Post-IPO Share Option Scheme**”) under Chapter 17 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited in order to provide the grantees of the Post-IPO Share Option Scheme with the opportunity to acquire proprietary interests in the Company, which will encourage the grantees to work towards enhancing the values of the Company and in turn benefiting the Company and its shareholders (the “**Shareholders**”) as a whole.

The Post-IPO Share Option Scheme is subject to, among other things, (i) the listing committee of The Stock Exchange of Hong Kong Limited granting approval for the listing of, and permission to deal in, the shares of the Company which may be issued upon the exercise of the options which may be granted under the Post-IPO Share Option Scheme, and (ii) the approval of the Shareholders at a general meeting of the Company (the “**General Meeting**”) to be convened for the purpose of considering and, if thought fit, approving the adoption of the Post-IPO Share Option Scheme.

A circular containing further details about the Post-IPO Share Option Scheme and a notice for the General Meeting will be despatched to the Shareholders in due course.

As of the date of this announcement, the Post-IPO Share Option Scheme remains subject to the approval of the Shareholders. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Company’s securities.

By Order of the Board

Alphamab Oncology

Dr. XU Ting

Chairman and Executive Director

Hong Kong, April 14, 2020

As at the date of this announcement, the Board comprises Dr. XU Ting as the Chairman and Executive Director and Ms. LIU Yang as Executive Director, Mr. XU Zhan Kevin and Mr. QIU Yu Min as Non-executive Directors, and Dr. JIANG Hualiang, Mr. WEI Kevin Cheng and Mr. WU Dong as Independent Non-executive Directors.